DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A-HeFT: old dog, new endothelial tricks.

Author(s): Cohn JN

Affiliation(s): Rasmussen Center for Cardiovascular Disease Prevention, Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA. cohnx001@umn.edu

Publication date & source: 2005, Tex Heart Inst J., 32(3):366-8.

Publication type: Review

In conclusion, reduced nitric oxide bioactivity contributes to cardiac and vascular remodeling. Nitricoxide-enhancing therapy can slow cardiac andvascular remodeling. African-Americans with heart failure exhibit nitric oxide deficiency and a dramatic benefit from nitric-oxide-enhancing therapy. The potential benefit of this therapy in other groups with heart failure and in other vascular remodeling disease processes requires further study.

Page last updated: 2007-02-12

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017